List of Excipients in Branded Drug 12 HOUR NASAL DECONGESTANT

« Back to Dashboard

Generic Drugs Containing 12 HOUR NASAL DECONGESTANT

Company	Ingredient	NDC	Excipient
CVS Pharmacy	pseudoephedrine hydrochloride	59779-703	CARNAUBA WAX
CVS Pharmacy	pseudoephedrine hydrochloride	59779-703	CELLULOSE, MICROCRYSTALLINE
CVS Pharmacy	pseudoephedrine hydrochloride	59779-703	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
CVS Pharmacy	pseudoephedrine hydrochloride	59779-703	HYPROMELLOSES
CVS Pharmacy	pseudoephedrine hydrochloride	59779-703	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in 12 HOUR NASAL DECONGESTANT?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CASTOR OIL
2	CELLULOSE, MICROCRYSTALLINE
1	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
1	HYPROMELLOSE

12-Hour Nasal Decongestant Excipient Strategy and Commercial Opportunities

Last updated: October 15, 2026

A 12-hour nasal decongestant is typically an over-the-counter oxymetazoline hydrochloride product at 0.05% strength. The commercial opportunity is primarily in formulation differentiation, preservative reduction, delivery-device performance, pediatric positioning, private-label manufacturing, and international regulatory adaptation rather than in new-molecule exclusivity. Oxymetazoline nasal products generally fall within the FDA OTC nasal decongestant framework under 21 C.F.R. § 341.20, subject to the applicable Drug Facts labeling and concentration requirements.[1]

What active ingredient is used in a 12-hour nasal decongestant?

Most 12-hour nasal decongestant sprays use oxymetazoline hydrochloride 0.05%. The active ingredient is an alpha-adrenergic agonist that constricts nasal blood vessels and reduces congestion. Relief is marketed as lasting up to 12 hours.

Product characteristic	Typical commercial specification
Active ingredient	Oxymetazoline hydrochloride
Standard adult strength	0.05%
Typical pediatric strength	0.025%
Dosage form	Metered nasal spray or pump spray
Regulatory category	OTC nasal decongestant
Typical dosing interval	Every 10 to 12 hours
Primary markets	United States, Canada, Europe, Latin America, Asia
Key commercial risk	Rebound congestion from prolonged use

The 0.05% concentration is used for adults and children six years of age and older in common U.S. labeling. Lower-strength products are used for younger children where permitted by the applicable label and jurisdiction.[1]

What excipients are used in oxymetazoline nasal spray formulations?

Commercial formulations generally require a vehicle, pH-control system, tonicity agent, microbial-control strategy, and packaging-compatible preservative system. Exact excipient selection varies by manufacturer and is not fixed by the OTC monograph.

Core excipient functions

Excipient function	Common options	Formulation purpose	Main development issue
Vehicle	Purified water	Dissolves oxymetazoline hydrochloride and supports nasal delivery	Microbial control and stability
Tonicity adjustment	Sodium chloride, dextrose	Improves nasal tolerability	Osmolality must remain within an acceptable range
Buffer	Phosphate, citrate, acetate	Controls pH and stabilizes the solution	Irritation and preservative compatibility
Preservative	Benzalkonium chloride, phenoxyethanol, other accepted systems	Controls microbial growth in multidose packaging	Mucosal tolerability and regulatory acceptability
Chelator	Disodium edetate	Binds trace metals and can improve preservative performance	Compatibility and regulatory justification
Viscosity modifier	Hypromellose or similar polymer	Extends residence time and reduces run-off	Spray pattern, dose uniformity, and device clogging
Solubilizer or surfactant	Product-specific	Supports wetting or formulation robustness	Nasal irritation and foaming
Antioxidant	Product-specific	Protects oxidation-sensitive components	May alter pH, taste, or tolerability

Published product labels show that commercial oxymetazoline products may contain combinations of purified water, sodium chloride, phosphate salts, benzalkonium chloride, disodium edetate, hypromellose, and other inactive ingredients.[2] The inactive-ingredient list is product-specific and should be verified against the current DailyMed label and FDA Inactive Ingredient Database before a formulation is selected.[2,3]

Which excipient strategy is best for a 12-hour nasal spray?

The strongest baseline strategy is a clear, aqueous, isotonic or near-isotonic solution with controlled pH, low particulate burden, validated preservative performance, and a pump that delivers a reproducible metered dose.

Baseline commercial formulation

A conventional multidose product can use:

• Purified water as the vehicle.
• Sodium chloride for tonicity.
• A phosphate or citrate buffer.
• A low concentration of an accepted preservative.
• Disodium edetate to improve preservation robustness.
• No viscosity modifier unless residence time or run-off is a commercial objective.

This design minimizes manufacturing complexity and supports a low-cost private-label product. It also aligns with the dominant market presentation: a small multidose bottle with a mechanical spray pump.

Premium formulation

A premium product can differentiate through:

• Preservative-free unit-dose packaging.
• A preservative-free multidose pump with validated microbial protection.
• Reduced benzalkonium chloride exposure.
• Controlled osmolality.
• A mild buffer system.
• A low-level viscosity modifier designed to improve nasal retention.
• A pump that produces a consistent plume and limits post-use dripping.

The main risk is that premium excipient systems can increase cost, device-development time, and extractables or leachables testing. A higher-cost formulation must support a clear claim, such as preservative-free delivery, reduced irritation, or improved spray performance.

What formulation patents protect 12-hour nasal decongestants?

The active ingredient itself has limited modern exclusivity value. Oxymetazoline has been marketed for decades, and conventional oxymetazoline solutions are generally exposed to generic and private-label competition.

Patentable subject matter can still arise from:

1. Preservative-free multidose delivery systems.
2. Pump and container designs that maintain sterility or microbial control.
3. Specific excipient ratios.
4. Low-irritation formulations.
5. Mucoadhesive or viscosity-enhanced systems.
6. Unit-dose containers.
7. Combination products containing oxymetazoline and another active ingredient.
8. Manufacturing processes that improve impurity control or spray uniformity.
9. Device-enabled dose counters or misuse-limiting systems.
10. Formulations designed for specific pediatric or postoperative populations.

A patent directed only to oxymetazoline hydrochloride in water and sodium chloride would face substantial validity and obviousness pressure. A stronger estate would combine composition claims with device claims, microbial-control performance, stability data, and measurable spray characteristics.

How strong is the patent estate for oxymetazoline nasal spray?

Patent category	Relative strength	Commercial assessment
Oxymetazoline active ingredient	Low	Long-established active ingredient with broad competition
Conventional aqueous solution	Low	Easy for competitors to design around
Specific preservative system	Moderate	Strength depends on narrow claim language and data
Preservative-free multidose package	Moderate to high	Device and formulation integration can create barriers
Mucoadhesive formulation	Moderate	Requires meaningful performance differentiation
Combination product	Moderate	Depends on clinical and regulatory support
Spray-pump architecture	Moderate	Device patents may expire independently of formulation patents
Manufacturing process	Moderate	Stronger when impurity or dose-uniformity advantages are demonstrated

Patent analysis must be conducted against the specific brand, manufacturer, formulation, and jurisdiction. There is no single patent estate for the generic label description "12 Hour Nasal Decongestant."

What is the FDA regulatory status of a 12-hour nasal decongestant?

A standard oxymetazoline nasal spray is generally regulated as an OTC drug rather than as a prescription product or biologic. The relevant U.S. framework is the OTC nasal decongestant monograph and associated labeling requirements.[1]

The product must address:

• Active ingredient identity and concentration.
• Dosage instructions.
• Age restrictions.
• Warnings against prolonged use.
• Rebound congestion.
• Contraindications and medical consultation language where applicable.
• Container and closure suitability.
• Dose delivery and fill-volume controls.
• Microbial quality.
• Stability through labeled shelf life.

A conventional monograph-compliant product does not require the same clinical development program as a novel prescription nasal therapy. A formulation that departs from the monograph, introduces a new combination, or makes material therapeutic claims may require a different FDA pathway.

Does a 12-hour nasal decongestant have Orange Book listings?

Ordinary OTC monograph products are generally not treated like approved prescription products with Orange Book-listed patents and exclusivity. A standard oxymetazoline nasal spray therefore typically has no meaningful Orange Book patent barrier comparable to a branded prescription medicine.

This changes if a product is approved through an NDA or another route outside the standard OTC monograph framework. The regulatory status must be assessed by specific product and application number rather than by the marketing phrase "12 Hour Nasal Decongestant."

When does a 12-hour nasal decongestant lose exclusivity?

For a conventional oxymetazoline OTC product, there is usually no commercially meaningful new-molecule exclusivity period remaining. The product competes through monograph compliance, manufacturing cost, retail placement, brand recognition, packaging, and formulation differentiation.

Exclusivity mechanism	Relevance to conventional oxymetazoline spray
New chemical entity exclusivity	Not commercially relevant
Prescription NDA exclusivity	Usually not applicable
Biosimilar exclusivity	Not applicable
Orange Book patent listing	Usually not applicable for monograph OTC products
Formulation patent	Potentially relevant if claims are valid and enforceable
Device patent	Potentially relevant
Trademark protection	Often commercially important
Retail or private-label exclusivity	Contractual rather than statutory

Are there Paragraph IV challenges for 12-hour nasal decongestants?

Paragraph IV litigation is generally associated with abbreviated new drug applications referencing listed prescription drugs. A conventional OTC monograph oxymetazoline spray is not normally exposed to the same Paragraph IV structure.

Competitive disputes are more likely to involve:

• Trademark infringement.
• False or misleading comparative advertising.
• Packaging and trade dress.
• Patent claims directed to a device or specialized formulation.
• FDA classification or monograph compliance.
• Product liability related to misuse or contamination.
• Retailer or contract-manufacturing disputes.

The absence of a typical Paragraph IV pathway reduces litigation barriers for new entrants. It also limits the defensive value of a conventional formulation patent unless the patent covers a meaningful, difficult-to-design-around feature.

What formulation opportunities exist for 12-hour nasal decongestants?

Preservative-free multidose delivery

Preservative-free delivery is the clearest premium opportunity. Benzalkonium chloride has been used widely in nasal products, but concerns about mucosal irritation and ciliary effects create a rationale for preservative-free alternatives, particularly for frequent users and patients with sensitive nasal tissue.[4]

The commercial challenge is microbial protection. A preservative-free multidose package must rely on container engineering, one-way valves, filtered venting, antimicrobial materials, or a validated design that limits contamination. The device becomes part of the product’s regulatory and intellectual-property strategy.

Unit-dose packaging

Unit-dose ampoules or single-use spray containers can remove the need for a preservative. They are suitable for:

• Travel products.
• Hospital and clinic use.
• Postoperative nasal care.
• Premium retail products.
• Patients who prefer reduced preservative exposure.

The disadvantages are higher packaging cost, more material usage, increased shipping volume, and less convenience for repeated daily use.

Low-irritation formulations

A low-irritation platform can use controlled pH, reduced preservative concentration, appropriate osmolality, and a low-shear pump. Marketing claims must be supported by product testing and cannot imply clinical superiority without adequate evidence.

Residence-time enhancement

A modest increase in viscosity may reduce throat drip and improve nasal residence time. Hypromellose and related polymers are possible candidates, but the formulation must preserve:

• Spray pattern.
• Droplet-size distribution.
• Dose uniformity.
• Pump recovery.
• Container emptying.
• Absence of nozzle clogging.

Viscosity enhancement is more defensible when linked to measured delivery performance rather than a broad claim of longer action. Oxymetazoline already has a long marketed dosing interval, so an excipient change alone may not justify a new 12-hour claim.

Pediatric positioning

A lower-strength 0.025% product can support pediatric segmentation where permitted by the applicable regulatory framework. Pediatric products require particular attention to dosing errors, actuator force, package size, and age-specific labeling. Unit-dose packaging can reduce accidental overuse but may increase per-dose cost.

Combination nasal products

Potential combinations include oxymetazoline with saline, moisturizers, or other nasal-care components. The regulatory burden increases when another active drug is added. A simple saline adjunct may support consumer positioning, but it does not automatically establish a therapeutic advantage.

What manufacturing and IP barriers affect market entry?

Manufacturing barriers are moderate rather than high. The liquid formulation is relatively simple, but nasal spray production requires validated controls for:

• Assay and impurities.
• pH and osmolality.
• Bioburden and microbial limits.
• Preservative effectiveness.
• Delivered volume.
• Spray content uniformity.
• Droplet or particle-size distribution.
• Pump actuation force.
• Container-closure integrity.
• Extractables and leachables.
• Stability after repeated opening and use.

The highest-value manufacturing capability is often the spray-pump platform rather than the bulk liquid itself. A reliable pump supplier, validated filling line, and stable container-closure system can reduce launch risk more effectively than a complex excipient package.

Which companies are competing in 12-hour nasal decongestants?

The market includes branded products, store brands, contract manufacturers, and regional generic suppliers. Afrin is the best-known U.S. branded oxymetazoline platform, while retailers sell multiple private-label equivalents. Competition is based on price, distribution, brand trust, packaging, and perceived tolerability.

Competitive segment	Typical strategy
National brand	Brand recognition, broad retail distribution, premium pricing
Store brand	Low price, monograph-compliant formulation
Generic manufacturer	Scale manufacturing and retailer supply
Premium nasal-care brand	Preservative-free, moisturizing, or device differentiation
Hospital supplier	Unit-dose packaging and institutional procurement
Regional manufacturer	Local regulatory registration and lower logistics cost

A new entrant is unlikely to win with oxymetazoline alone. A stronger proposition combines a differentiated package with a credible user benefit, such as preservative-free multidose delivery, lower run-off, improved actuation, or a lower-cost pediatric presentation.

What licensing deals and commercial partnerships are available?

The most practical partnership opportunities are:

1. Private-label supply agreements with pharmacy and mass-retail chains.
2. Contract development and manufacturing arrangements.
3. Licensing of preservative-free pump technology.
4. Co-development with nasal-device manufacturers.
5. Regional distribution agreements.
6. Hospital and institutional supply contracts.
7. Combination-product partnerships with saline or nasal-care brands.

Traditional molecule licensing is less attractive because oxymetazoline is a mature active ingredient. Device and packaging technology can command more strategic value than the API. A company with a validated preservative-free multidose system may license the platform across several nasal products rather than rely on a single decongestant SKU.

What generic launch scenarios exist for 12-hour nasal decongestants?

Low-cost conventional launch

The entrant uses a standard aqueous oxymetazoline formulation, a conventional pump, and a low-cost bottle. This has the fastest path to market but the weakest differentiation. Retail distribution and manufacturing price determine success.

Premium preservative-free launch

The entrant uses a higher-cost pump or unit-dose package and targets consumers concerned about preservatives. This approach can support higher pricing but requires stronger stability, microbial-control, device, and consumer-education programs.

Pediatric launch

The entrant develops a lower-strength product with age-specific dosing and a child-resistant or dose-limiting presentation. The opportunity is narrower but can improve portfolio breadth.

International adaptation

Excipients, preservatives, labeling, and permitted concentrations vary by jurisdiction. A modular formulation using widely accepted excipients can reduce registration complexity. The same pump may not be transferable across markets without local extractables, performance, and packaging review.

Key Takeaways

• A 12-hour nasal decongestant is typically an oxymetazoline hydrochloride 0.05% OTC nasal spray.
• The active ingredient has limited exclusivity value; formulation, device, packaging, and distribution drive commercial differentiation.
• The baseline formulation should prioritize aqueous solubility, controlled pH, acceptable tonicity, microbial protection, and dose uniformity.
• Preservative-free multidose delivery is the strongest premium excipient and device opportunity.
• Unit-dose packaging reduces preservative requirements but raises cost and material use.
• Conventional products generally do not have meaningful Orange Book or Paragraph IV barriers.
• The most defensible patent strategy combines excipient composition claims with pump, container, microbial-control, and spray-performance claims.
• Private-label supply, contract manufacturing, and nasal-device licensing are more realistic commercial paths than molecule licensing.
• Manufacturing capability and pump performance can create greater market-entry barriers than the liquid formulation.
• Any launch must control rebound-congestion labeling, age restrictions, microbial quality, and delivered-dose performance.

FAQs About 12-Hour Nasal Decongestant Excipient Strategy

Can benzalkonium chloride be used in a 12-hour oxymetazoline spray?

Yes. Benzalkonium chloride is used in some commercial nasal products, but its concentration, compatibility, preservative effectiveness, and nasal tolerability must be evaluated for the specific formulation and package.

Is a preservative-free oxymetazoline spray commercially viable?

Yes. The strongest formats are unit-dose containers and multidose systems with validated microbial-control technology. The commercial case depends on whether consumers and retailers will support the higher package cost.

Does hypromellose extend oxymetazoline relief beyond 12 hours?

Not automatically. Hypromellose may affect residence time and run-off, but an extended-duration claim requires product-specific performance and clinical support.

Can a retailer launch a private-label 12-hour nasal decongestant?

Yes. A retailer can source a monograph-compliant product through a qualified contract manufacturer, subject to labeling, quality, manufacturing, packaging, and regulatory requirements.

Is oxymetazoline subject to biosimilar competition?

No. Oxymetazoline is a small-molecule drug, not a biologic. Competition occurs through OTC monograph products, generic supply, private-label products, and formulation or device differentiation.

References

1. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 341.20: Labeling of nasal decongestant drug products. Electronic Code of Federal Regulations.

2. National Library of Medicine. (2024). DailyMed: Oxymetazoline hydrochloride nasal spray product labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2002). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation. Guidance for industry.